Whereas globally, approximately 1 in 5 people develops cancer during their lifetime, and 1 in 8 men and 1 in 11 women die from the disease; Whereas the estimated global economic cost of cancer over the next three decades will reach over $25,000,000,000,000, with the United States facing the second-largest economic costs of cancer; Whereas it is estimated that in 2023, more than 1,900,000 new cancer cases and more than 600,000 cancer deaths occurred in the United States; Whereas, although cancer incidence and mortality rates decreased overall for all racial and ethnic groups, African Americans and American Indians/Alaska Natives continue to have disproportionately higher rates of cancer than Whites (according to the American Cancer Society’s Cancer Facts and Figures report); Whereas targeted cancer screening programs can effectively identify high-risk populations; Whereas research shows that the overall cancer screening rates are lower among African Americans, Latinos, Asian Americans, and American Indian/Alaska Natives than Whites; Whereas prevention and early detection initiatives can help significantly reduce cancer care disparities and inequities, and improve patient outcomes; Whereas recent findings suggest that people of color, when compared to Whites, receive later diagnoses for some types of cancer; Whereas increased patient navigation services can play a crucial role in reducing barriers to timely and appropriate cancer screenings and care by guiding patients through the complex health care system; Whereas expanding racial and ethnic diversity in clinical trials ensures the inclusivity of all populations and improves the generalizability of vitally important research findings; Whereas the underrepresentation of people of color, from both urban and rural communities, in clinical trials perpetuates and exacerbates racial and ethnic cancer inequities and disparities, and limits access to potentially lifesaving treatments